A randomised study and an extension study of brexpiprazole in patients with borderline personality disorder.

Brexpiprazole was associated with nominally significant improvements in ZAN-BPD total score versus placebo at Week 8 (LSMD −1.88; 95% CLs −3.57, −0.19; p = 0.029) and Week 12 (LSMD −2.30; 95% CLs −4.04, −0.55; p = 0.010).

also in 7,732 other papers